We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
iTeos Therapeutics Inc | NASDAQ:ITOS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.04 | 9.68% | 11.78 | 11.40 | 12.29 | 11.81 | 10.6039 | 10.81 | 408,578 | 00:57:14 |
1. Name and Address of Reporting Person * GADICKE ANSBERT | 2. Issuer Name and Ticker or Trading Symbol iTeos Therapeutics, Inc. [ ITOS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 11/30/2021 | S(1) | 9809 (2)(3) | D | $34.62 (4) | 4943551 | I | See Footnote (5) | ||
Common Stock | 11/30/2021 | S(1) | 46992 (6) | D | $35.19 (7) | 4896559 | I | See Footnote (8) | ||
Common Stock | 12/1/2021 | S(1) | 10111 (9) | D | $33.82 (10) | 4886448 | I | See Footnote (11) | ||
Common Stock | 12/1/2021 | S(1) | 9131 (12) | D | $34.61 (13) | 4877317 | I | See Footnote (14) | ||
Common Stock | 12/1/2021 | S(1) | 1500 (15) | D | $35.34 (16) | 4875817 | I | See Footnote (17) | ||
Common Stock | 12/2/2021 | S(1) | 49796 (18) | D | $33.74 (19) | 4826021 | I | See Footnote (20) | ||
Common Stock | 12/2/2021 | S(1) | 12434 (21) | D | $34.83 (22) | 4813587 | I | See Footnote (23) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
GADICKE ANSBERT C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142 | X | ||||
UBS Oncology Impact Fund L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142 | X | ||||
BioImpact Capital LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142 | X | ||||
Oncology Impact Fund (Cayman) Management L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142 | X |
Signatures | ||
/s/ Ansbert Gadicke | 12/2/2021 | |
**Signature of Reporting Person | Date | |
/s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P., the general partner of UBS Oncology Impact Fund L.P | 12/2/2021 | |
**Signature of Reporting Person | Date | |
/s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC | 12/2/2021 | |
**Signature of Reporting Person | Date | |
/s/ Ansbert Gadicke, managing partner of BioImpact Capital LLC, the general partner of Oncology Impact Fund (Cayman) Management L.P. | 12/2/2021 | |
**Signature of Reporting Person | Date |
1 Year iTeos Therapeutics Chart |
1 Month iTeos Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions